Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death
While treatment is believed to influence diseaseoutcome, the wide variation in published survival andremission rates among chronic myeloid leukemia (CML)patients demonstrates that the effectiveness oftreatment appears to be modified by patientcharacteristics, disease features, and diseasemanagement approaches. Future improvements in thetreatment of CML are dependent on our ability todistinguish between patients who are likely to havelong-term disease free survival and those who are not.Between June 1982 and December 2002, 234 patientswith CML in first chronic phase (CP) were treated atthe City of Hope National Medical Center with anallogeneic blood or marrow transplant (Allo-BMT)using histocompatible sibling donors. Thisretrospective case-s
List Price: $ 86.67
Price: $ 86.67
Leukemia — Comprehensive overview covers symptoms, causes, risk factors, treatment of this blood-related cancer.
Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death
Find More Leukemia Relapse Products
Orignal From: Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death
No comments:
Post a Comment